The first randomised trial to investigate the treatment of low bone density in young people with cystic fibrosis (CF), published Online First in The Lancet Respiratory Medicine, provides compelling evidence that alendronate (a drug that curbs bone loss) is safe and can help increase bone mineral density (BMD) in young patients with CF after standard treatment with calcium and vitamin D has failed. Improvements in treatments have increased the life expectancy of people with CF to about 40 years, putting them at high risk of long-term complications such as osteoporosis and bone fractures...
More...
More...